BioLineRx in deal with Univ. of Illinois

Financial terms of the deal, the company's first with a US university, were not disclosed.

By JERUSALEM POST BUSINESS STAFF
July 23, 2007 07:57

BioLineRx Ltd. and the University of Illinois at Urbana-Champaign said Sunday they reached an exclusive worldwide licensing agreement for the research, development and commercialization of BL-4030, an apoptosis agent to treat cancer. Financial terms of the deal, the company's first with a US university, were not disclosed.


Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS